Butylated Hydroxyanisole vs Butylated Hydroxyanisole: which is worse?
Quick answer: Butylated Hydroxyanisole carries the heavier risk profile. Butylated Hydroxyanisole is — in the EU and — in the US; Butylated Hydroxyanisole is — in the EU and — in the US.
| Property | Butylated Hydroxyanisole | Butylated Hydroxyanisole |
|---|---|---|
| EU status | — | — |
| US status | — | — |
| Risk level | — | — |
| Banned in | Japan (banned for use in foods containing fats and oils) | Japan (banned for foods containing fats and oils) |
| Restricted in | European Union (restricted; banned in baby food), United Kingdom, Australia/New Zealand (ADI-based limits) | European Union (restricted; banned in baby food), United Kingdom |
| Category | additive | additive |
| Where it hides | — | — |
What is Butylated Hydroxyanisole?
Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.
What is Butylated Hydroxyanisole?
Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum (see also bha entry). It is a mixture of 2-BHA and 3-BHA isomers, used to prevent oxidative rancidity in fats, oils, and fat-containing foods. Chemical formula C11H16O2.
Documented risks
Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.
Butylated Hydroxyanisole: IARC classifies BHA as Group 2B (possible human carcinogen) based on forestomach tumor studies in rodents at high doses. The NTP lists it as 'reasonably anticipated to be a human carcinogen.' EFSA's 2012 review found endocrine-disrupting potential. Japan banned it for food use. The FDA permits it at 0.02% of fat content. Concerns about estrogen-receptor interaction have been documented in animal studies. Contact dermatitis from cosmetic use is reported.
Scan a barcode and we'll flag both Butylated Hydroxyanisole and Butylated Hydroxyanisole (plus 200+ other ingredients banned overseas).
Scan free →